FDA clears Eli Lilly's oral GLP-1 Foundayo (orforglipron) for obesity

FDA approved Eli Lilly's oral GLP-1 drug orforglipron (Foundayo) April 1 for obesity. It's the first oral GLP-1 obesity medicine with no food or water requirements and free dosing—head-to-head to injectables Wegovy and Zepbound. Q1's most operationally impactful approval.